Nostrum Laboratories recalls lots of metformin tablets after nitrosamine detection
Company is the latest in a lengthening list of pharma companies recalling the diabetes medicine over unacceptable levels of NDMA
Nostrum Laboratories has become the latest pharmaceutical company to voluntarily recall lots of its version of diabetes medicine, metformin, after they were found to contain excessive levels of nitrosamine impurities.
The Missouri-based company said it is recalling two lots of 750 mg metformin HCl extended release tablets, which were found to contain levels of N-Nitrosodimethylamine (NDMA) above the US Food and Drug Administration’s ADI limit of 96 ng/day.
NDMA, a chemical form of nitrosamine, is classified as a probable human carcinogen and a possible cause of cancer.
Nostrum said it has not received any reports of adverse events related to the recall. It added it is notifying its distributors by letter and is arranging for return of all recalled products.
The case in the latest in a series of metformin recalls due to the presence of nitrosamine by pharmaceutical companies, including Amneal, Lupin and Marksans.
Metformin is used to treat type II diabetes and is designed to lower glucose levels.
Nitrosamines are genotoxic substances which may increase the risk of cancer in people exposed to above acceptable levels over longer periods of time. The issue of contamination in pharmaceutical products first arose in 2018 when the FDA detected impurities in Angiotensin II receptor blockers (ARBs).
Soon after, several ‘sartan’ medicines were also found to include nitrosamine impurities, leading to product recalls and a new set of manufacturing requirements for those medicines.
And most recently, the European Medicine Agency’s Committee on Human Medicinal Products said it was asking marketing authorization holders for medicines containing metformin – an oral drug used to control high blood sugar in patients with type II diabetes -- to test their medicines for nitrosamine before releasing them onto the market.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance